Project Grant R01NS133339
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$474K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
The federal Project Grant award R21NS142585 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The $460,940 award, effective June 1, 2025 through May 31, 2027, supports research by The University of Texas MD Anderson Cancer Center to investigate the impact of glioma-associated germline risk alleles on neurodevelopmental trajectories. The goal is to...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $443,354 to the University of Pittsburgh to conduct research on targeting the hexosamine biosynthetic pathway in pediatric brain tumors, specifically diffuse midline gliomas (DMG) harboring the H3K27M mutation. The research aims to investigate how this metabolic pathway supports tumor growth...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a 24-month, $430,375 Project Grant (CFDA 93.853) to Emory University to develop human organoid models for pediatric high-grade gliomas (PHGGs). The research aims to 1) create PHGG organoid models using human patient-derived cancer stem cells and 2) model how interactions between PHGG cells and the human neural microenvironment affect responses to tyrosine kinase inhibitors and other anti-tumor drugs. The goal is to...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $717,802 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the University of Georgia Research Foundation, Inc. The grant supports research aimed at elucidating the cellular and molecular mechanisms underlying the development of a subtype of high-grade glioma brain tumors known as HGG-G34. Specifically, the research project seeks to unravel the...
This federal Project Grant award for $142,452.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The funding supports research to develop novel mRNA-based gene therapies for the treatment of diffuse midline glioma (DMG), a lethal pediatric brain tumor. The principal investigator will optimize the delivery of mRNA using lipid nanoparticles to target the...
This federal Project Grant award of $604,852.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to investigate the role of glial progenitor cells in the initiation and recurrence of medulloblastoma, the most common malignant childhood brain tumor. The research aims to advance the understanding of tumor heterogeneity,...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program, will fund research to target cell-scaffolding proteins that contribute to radioresistance in glioblastoma, an aggressive brain cancer. The $448,250 award to The Research Foundation For The State University Of New York, operating as Upstate Medical Center, will support a 2-year...
This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $655,306 to The Regents of the University of California, San Francisco (UCSF) to develop and evaluate a therapeutic strategy that combines a brain-penetrant glyoxalase 1 (GLO1) inhibitor with radiation for the treatment of isocitrate dehydrogenase-mutant (IDHm) gliomas, one of the deadliest forms of brain cancer. The project aims to mechanistically validate reactive metabolite...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) totaling $949,312 provides funding for the University of Florida to develop a "next-generation" precision adoptive cell therapy (ACT) approach for the treatment of pediatric high-grade gliomas. The project aims to utilize patient-specific antigen profiling, a novel gene enrichment strategy, and a selective expansion platform to generate enriched, polyclonal tumor-reactive T...